Pfizer Inc. has been slower than some of its peers in executing value-based contracts with payers and that's because it believes that meaningful deals aren't very workable in the current system, Chairman and CEO Ian Read suggested during a policy discussion on health care system value in Washington, DC Sept. 19.
"We've been struggling to do value-based contracting with payers and providers," he said. "We have about 18 different projects underway but we've achieved [only] one." A company spokesperson would not...